ArticlePloS one2025
New insights into the molecular biology of Alzheimer's-like cerebral amyloidosis achieved through multi-omics approaches.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOne of the neuropathologic hallmarks of Alzheimer's disease (AD) is amyloid plaques composed of fibrillar amyloid beta (Aβ) that accumulate in the hippocampus and cerebral cortex. The identification of molecular changes and interactions associated with Aβ-dependent cerebral amyloidosis is a need in the field. We hypothesize that structured datasets linking proteins to differentially abundant metabolites may provide an indirect but effective means of elucidating the processes and functions in which these metabolites are involved. The goal of this study was to identify core network modules related to AD-like cerebral amyloidosis to provide new insights into the molecular underpinnings of this brain disorder potentially associated with diet and microbiota modulation.
methodsWe performed fecal bacterial genotyping and untargeted metabolomic analysis of plasma and feces from wild-type and McGill-R-Thy1-APP transgenic (Tg) rats, a model of AD-like cerebral amyloidosis, that were exposed to a high-fat diet protocol. To identify relevant proteins associated with the discriminant metabolites, we used several structured databases. Protein-metabolite associations (both physical and functional) were retrieved, and a collection of AD-associated protein-protein interaction (PPI) networks were built using a near-neighborhood approach.
resultsA total of 44 bacterial genera and 636 plasma and 576 fecal metabolites were analyzed. From the discriminating metabolites of the Sparse Partial Least Squares Discriminant Analysis (sPLS-DA) models, 657 networks were collected and a subset of the top 20 exploratory networks was defined. The first ranked network in terms of seed protein enrichment and number of participating metabolites showed strong biological signals of innate and adaptive immunity processes, with CD36 emerging as a central hub, orchestrating immunity, metabolic pathways, and fatty acid trafficking.
conclusionsThe network biology approach enabled a precise definition of the metabolic pathways underlying the disease biology highlighting the role of immune system in the complex interaction of the brain-gut axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.